Wang MH, Fang H, Xie C. Advanced glycation end products in gastric cancer: A promising future. World J Clin Oncol 2024; 15(9): 1117-1121 [PMID: 39351465 DOI: 10.5306/wjco.v15.i9.1117]
Corresponding Author of This Article
Chuan Xie, MD, Chief Doctor, Teacher, Department of Gastroenterology, The First Affiliated Hospital of Nanchang University, The Jiangxi Medical College, The Nanchang University, No.17 Yongwaizheng Street, Nanchang 330006, Jiangxi Province, China. xcsghhz@ncu.edu.cn
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Oncol. Sep 24, 2024; 15(9): 1117-1121 Published online Sep 24, 2024. doi: 10.5306/wjco.v15.i9.1117
Advanced glycation end products in gastric cancer: A promising future
Meng-Hui Wang, Hui Fang, Chuan Xie
Meng-Hui Wang, Hui Fang, Chuan Xie, Department of Gastroenterology, The First Affiliated Hospital of Nanchang University, The Jiangxi Medical College, The Nanchang University, Nanchang 330006, Jiangxi Province, China
Co-first authors: Meng-Hui Wang and Hui Fang.
Author contributions: Wang MH and Fang H wrote the manuscript; Xie C revised the manuscript; all authors have read and approved the final manuscript.
Supported byThe National Natural Science Foundation of China, No. 82100599 and No. 81960112; The Jiangxi Provincial Department of Science and Technology, No. 20212ACB216003; The Science and Technology Plan of Jiangxi Provincial Administration of Traditional Chinese Medicine, No.2023Z021; and The Young Talents Project of Jiangxi Provincial Academic and Technical Leaders Training Program for Major Disciplines, No. 20204BCJ23022.
Conflict-of-interest statement: The authors declare no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Chuan Xie, MD, Chief Doctor, Teacher, Department of Gastroenterology, The First Affiliated Hospital of Nanchang University, The Jiangxi Medical College, The Nanchang University, No.17 Yongwaizheng Street, Nanchang 330006, Jiangxi Province, China. xcsghhz@ncu.edu.cn
Received: March 13, 2024 Revised: July 19, 2024 Accepted: August 2, 2024 Published online: September 24, 2024 Processing time: 168 Days and 23.9 Hours
Abstract
In this editorial, we delve into the article and offer valuable insights into a crucial aspect of gastric cancer aetiology. Gastric cancer is a malignancy emanating from the epithelial lining of the gastric mucosa and one of the most prevalent forms of cancer worldwide. The development of gastric cancer is associated with multiple risk factors, including Helicobacter pylori infection, advanced age, a diet rich in salt, and suboptimal eating patterns. Despite notable reductions in morbidity and mortality rates, gastric cancer remains a formidable public health concern, impacting patients’ lives. Advanced glycation end products (AGEs) are complex compounds arising from nonenzymatic reactions within living organisms, the accumulation of which is implicated in cellular and tissue damage; thus, the levels are AGEs are correlated with the risk of diverse diseases. The investigation of AGEs is of paramount importance for the treatment of gastric cancer and can provide pivotal insights into disease pathogenesis and preventive and therapeutic strategies. The reduction of AGEs levels and suppression of their accumulation are promising avenues for mitigating the risk of gastric cancer. This approach underscores the need for further research aimed at identifying innovative interventions that can effectively lower the incidence and mortality rates of this malignancy.
Core Tip: Gastric cancer is a widespread malignancy that is linked to multiple risk factors. Advanced glycation end products (AGEs) are closely correlated with gastric cancer pathogenesis. Decreasing AGEs levels and minimizing AGEs accumulation may slow gastric cancer progression. Future research endeavours should aim to discover novel interventions to reduce the burden of gastric cancer and improve human health.
